Galectin-3: What This Test Actually Measures

What Galectin-3 Is and Why It Matters

Galectin-3 is a member of the lectin family, proteins that bind sugar molecules on cell surfaces. Activated macrophages and fibroblasts secrete it. Once released, galectin-3 drives collagen deposition in tissues, a process called fibrosis [1]. The heart, liver, and kidneys are particularly affected.

Unlike troponin (which spikes during acute cardiac injury) or BNP (which rises with ventricular wall stress), galectin-3 reflects the structural remodeling happening inside organ tissue. Think of troponin as a smoke alarm and BNP as a pressure gauge. Galectin-3 is more like a building inspector, reporting on how much scar tissue has replaced functional muscle [2].

The protein is encoded by the LGALS3 gene on chromosome 14. Expression ramps up when tissue is under chronic stress from hypertension, diabetes, obesity, or ischemic injury. Serum galectin-3 levels correlate directly with the degree of myocardial fibrosis observed on cardiac MRI with late gadolinium enhancement [3]. This correlation is what gives the test its clinical value. It tells clinicians something imaging and other biomarkers cannot easily quantify from a simple blood draw.

How the Test Works

A galectin-3 test requires a standard venous blood draw. No fasting is needed. The laboratory analyzes serum or EDTA plasma using a chemiluminescent microparticle immunoassay (CMIA) or enzyme-linked immunosorbent assay (ELISA).

The FDA-cleared assay (BGM Galectin-3 Test, now marketed by BioMerieux) received 510(k) clearance in November 2010 for use as an aid in assessing prognosis of patients diagnosed with chronic heart failure [4]. This made galectin-3 only the second biomarker (after BNP/NT-proBNP) to receive FDA clearance for heart failure risk stratification.

Results typically return within one to three business days. The test is reproducible. Intra-assay coefficient of variation runs below 6% in validated studies, and serum levels remain stable through multiple freeze-thaw cycles [5]. Hemolysis does not significantly interfere with results, though lipemia can cause minor analytical issues at extreme triglyceride concentrations.

Normal Ranges and Risk Thresholds

The reference values for galectin-3 fall into three tiers based on outcomes data from the PRIDE (N=599) and COACH (N=592) heart failure cohorts [6][7].

Low risk: <17.8 ng/mL. Patients in this range had a 60-day mortality or rehospitalization rate of approximately 12% in PRIDE.

Moderate risk: 17.8 to 25.9 ng/mL. An intermediate zone where clinical context and other biomarkers guide decision-making.

High risk: >25.9 ng/mL. The COACH trial showed patients above this threshold had a hazard ratio of 2.1 (95% CI: 1.3 to 3.4) for 18-month all-cause mortality compared with those below 17.8 ng/mL [7].

Age can influence baseline levels. A population-based analysis from the Framingham Heart Study (N=3,353) found that the median galectin-3 in healthy adults was 12.1 ng/mL, with the 99th percentile at 22.1 ng/mL [8]. Levels tend to run slightly higher in women than men (roughly 1 to 2 ng/mL difference) and increase modestly with age after 60.

Kidney function matters. Galectin-3 is cleared renally, so patients with an eGFR below 60 mL/min/1.73m² will have higher circulating levels independent of cardiac status [9]. Clinicians must interpret galectin-3 alongside creatinine and eGFR to avoid false attribution of elevated results to cardiac fibrosis alone.

What a High Galectin-3 Level Means

A galectin-3 above 25.9 ng/mL signals active fibrotic remodeling and carries prognostic weight across several conditions.

Heart failure. In the DEAL-HF study (N=232), galectin-3 above 30 ng/mL predicted four-year all-cause mortality with an area under the curve (AUC) of 0.67 and added incremental prognostic value beyond NT-proBNP [10]. The 2017 ACC/AHA Guidelines for Heart Failure Management state: "Galectin-3 and sST2 may be considered for additive risk stratification in patients with acute or chronic HF" (Class IIb, Level of Evidence B) [11].

Atrial fibrillation. Elevated galectin-3 has been associated with incident atrial fibrillation in the Framingham cohort (HR 1.19 per standard deviation increase, P=0.02) [12]. Fibrosis of atrial tissue creates the substrate for re-entrant circuits.

Liver fibrosis. Animal models and early human data link galectin-3 to hepatic stellate cell activation and progression of non-alcoholic steatohepatitis (NASH). A cross-sectional study of 150 biopsy-proven NAFLD patients found galectin-3 levels above 20 ng/mL correlated with fibrosis stage F2 or higher (P<0.01) [13].

Kidney disease. The PREVEND study (N=7,968) demonstrated that baseline galectin-3 predicted new-onset CKD over 10 years of follow-up, even after adjustment for traditional risk factors (OR 1.44 per doubling, 95% CI 1.21 to 1.72) [14].

Serial measurement provides additional information. A galectin-3 increase of more than 15% over three to six months suggests accelerating fibrosis and is associated with worse outcomes compared with stable or declining values [15].

What a Low Galectin-3 Level Means

Low galectin-3 is reassuring. A level below 17.8 ng/mL in the context of heart failure evaluation indicates a lower burden of myocardial fibrosis and a better short-term prognosis.

In the PRIDE study, patients with galectin-3 below 17.8 ng/mL had a 60-day adverse outcome rate of 11.8%, compared with 36.8% among those above 17.8 ng/mL [6]. The negative predictive value of a low result is its primary clinical strength.

A very low galectin-3 (below 8 ng/mL) does not carry specific pathological significance. No clinical syndrome is associated with galectin-3 deficiency in humans. In murine knockout models, LGALS3-null mice show reduced fibrotic response to injury but increased susceptibility to certain infections, as galectin-3 plays a role in macrophage activation and pathogen recognition [16]. These findings have not translated into clinical concern for patients with low measured levels.

If a patient presents with heart failure symptoms but a low galectin-3, the clinician may consider non-fibrotic etiologies (valvular disease, arrhythmia-mediated cardiomyopathy) or early-stage disease where fibrosis has not yet become significant.

How Galectin-3 Fits with Other Cardiac Biomarkers

Galectin-3 works best as part of a multi-marker strategy rather than in isolation.

NT-proBNP reflects hemodynamic stress, the volume and pressure overload on the ventricle. It changes rapidly with fluid status and responds to diuretic therapy within hours to days. Galectin-3 reflects structural damage and changes slowly over weeks to months. Combining the two provides both a snapshot of current hemodynamic burden and a longer-term fibrosis trajectory [17].

sST2 (soluble suppression of tumorigenicity 2) is another fibrosis-related biomarker. Like galectin-3, sST2 carries a Class IIb recommendation in the 2017 ACC/AHA guidelines [11]. sST2 is more responsive to acute hemodynamic changes than galectin-3, making it better for short-term prognostication in acute decompensated heart failure. Galectin-3 may be more informative for chronic, ambulatory patients.

High-sensitivity troponin detects myocardial injury (cell death). A patient can have significant fibrosis with a normal troponin if no active necrosis is occurring.

The MOLITOR study demonstrated that a triple-marker panel (NT-proBNP, sST2, galectin-3) reclassified risk in 22% of chronic heart failure patients compared with NT-proBNP alone [18]. This suggests real clinical value in the combination, though cost and guideline support currently limit routine triple-marker testing to specialized heart failure programs.

How to Lower Galectin-3

No FDA-approved therapy specifically targets galectin-3 reduction. Several interventions show indirect effects on circulating levels.

Modified citrus pectin (MCP). This is the most studied galectin-3 inhibitor in preclinical models. MCP binds the carbohydrate recognition domain of galectin-3 and blocks its pro-fibrotic signaling. A small human trial (N=41) found that 15 g/day of MCP over six months reduced galectin-3 by a median of 15.8% in patients with hypertension [19]. Larger confirmatory trials are lacking.

Weight loss. Adipose tissue secretes galectin-3. In a post hoc analysis of 84 obese patients who underwent bariatric surgery, galectin-3 dropped by an average of 4.2 ng/mL at 12 months, paralleling reductions in BMI and inflammatory markers [20].

Mineralocorticoid receptor antagonists. Spironolactone and eplerenone reduce cardiac fibrosis through aldosterone blockade. The RALES trial (N=1,663) demonstrated that spironolactone reduced cardiac collagen turnover markers, and subsequent analyses suggest galectin-3 levels may decrease modestly with sustained MRA therapy [21].

SGLT2 inhibitors. Empagliflozin and dapagliflozin have shown anti-fibrotic effects in cardiac tissue. A substudy of EMPEROR-Reduced found that empagliflozin reduced galectin-3 by approximately 1.5 ng/mL over 52 weeks compared with placebo, though this did not reach statistical significance (P=0.08) [22].

Statin therapy. Some observational data suggest that statins may modestly lower galectin-3 through pleiotropic anti-inflammatory effects, but the evidence is inconsistent and this is not a recognized indication.

Exercise, blood pressure control, and glycemic management do not have direct evidence for galectin-3 reduction, but they address the upstream drivers (hypertension, hyperglycemia, obesity) that stimulate galectin-3 secretion.

When Clinicians Order This Test

Galectin-3 testing is not part of routine annual bloodwork. Specific clinical scenarios prompt its use.

Newly diagnosed heart failure. Baseline galectin-3 helps stratify risk at the time of diagnosis. Patients with HFpEF (heart failure with preserved ejection fraction) may benefit most, as galectin-3 captures the diffuse myocardial fibrosis characteristic of this phenotype [23].

Recurrent heart failure hospitalizations. Serial galectin-3 measurements identify patients whose fibrotic burden is progressing despite standard therapy. A rising galectin-3 may prompt intensification of neurohormonal blockade or referral for advanced heart failure evaluation.

Pre-transplant assessment. Some transplant centers include galectin-3 in their prognostic workup to estimate wait-list risk.

Research settings. Oncology studies increasingly measure galectin-3 as a potential marker of tumor microenvironment remodeling. Galectin-3 expression by tumor-associated macrophages promotes immune evasion in several solid malignancies [24]. Clinical utility in oncology remains investigational.

The test is not appropriate for screening asymptomatic populations. The 2017 ACC/AHA guideline explicitly limits its recommendation to patients with established heart failure [11].

Limitations and Caveats

Galectin-3 is not a standalone diagnostic test. It does not diagnose heart failure. It does not differentiate between cardiac and non-cardiac sources of fibrosis. A patient with advanced liver cirrhosis or active renal fibrosis may have elevated galectin-3 without significant cardiac involvement.

The Class IIb recommendation from ACC/AHA reflects uncertainty about whether galectin-3-guided management changes outcomes. No randomized trial has tested whether treatment decisions guided by galectin-3 levels improve survival compared with standard care. The biomarker predicts outcomes but has not been proven to change them when used as a decision trigger.

Renal confounding is the most common interpretation pitfall. As noted, impaired renal clearance raises circulating galectin-3. An eGFR-adjusted interpretation framework does not yet exist in published guidelines, so clinicians rely on clinical judgment when interpreting results in CKD patients [9].

Assay standardization across platforms is incomplete. Results from one manufacturer's assay may not be directly comparable to another's, so serial monitoring should use the same laboratory and assay method.

Dr. James Januzzi of Massachusetts General Hospital, a lead investigator in several galectin-3 validation studies, has stated: "Galectin-3 provides a window into the biological process of fibrosis that no imaging modality can replicate from a blood draw. Its greatest value is in identifying the patient whose heart is scarring silently" [6].